-
EP4110405
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4110405
| EP4110405 - ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 02.12.2022 Database last updated on 12.07.2024 | |
| Former | The international publication has been made Status updated on 03.09.2021 | ||
| Former | unknown Status updated on 03.04.2021 | Most recent event Tooltip | 04.12.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states MCSAF INSIDE ONOCOLOGY 1 rue Claude Thion 37000 Tours / FR | [2023/01] | Inventor(s) | 01 /
JUEN, Ludovic 37100 TOURS / FR | 02 /
BALTUS, Christine 37520 LA RICHE / FR | 03 /
DESGRANGES, Audrey 37250 VEIGNÉ / FR | 04 /
TOUZÉ, Antoine 37250 MONTBAZON / FR | 05 /
KERVARREC, Thibault 37250 VEIGNÉ / FR | 06 /
LEBLOND, Valérie 37230 FONDETTES / FR | 07 /
SAMIMI, Mahtab 37540 SAINT-CYR-SUR-LOIRE / FR | [2023/01] | Representative(s) | Cabinet Beau de Loménie 158, rue de l'Université 75340 Paris Cedex 07 / FR | [2023/01] | Application number, filing date | 21714002.9 | 26.02.2021 | [2023/01] | WO2021FR50332 | Priority number, date | FR20200001974 | 27.02.2020 Original published format: FR 2001974 | [2023/01] | Filing language | FR | Procedural language | FR | Publication | Type: | A1 Application with search report | No.: | WO2021170961 | Date: | 02.09.2021 | Language: | FR | [2021/35] | Type: | A1 Application with search report | No.: | EP4110405 | Date: | 04.01.2023 | Language: | FR | The application published by WIPO in one of the EPO official languages on 02.09.2021 takes the place of the publication of the European patent application. | [2023/01] | Search report(s) | International search report - published on: | EP | 02.09.2021 | Classification | IPC: | A61K47/68, A61P35/00 | [2023/01] | CPC: |
A61K47/6849 (EP,US);
A61K31/40 (US);
A61K47/68031 (EP,US);
A61K47/6865 (EP);
A61K47/6889 (EP);
A61P35/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/01] | Title | German: | ANTI-CD56-ANTIKÖRPER-WIRKSTOFF-KONJUGATE UND IHRE VERWENDUNG IN DER THERAPIE | [2023/01] | English: | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | [2023/01] | French: | CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-CD56 ET LEUR UTILISATION EN THÉRAPIE | [2023/01] | Entry into regional phase | 10.08.2022 | National basic fee paid | 10.08.2022 | Designation fee(s) paid | 10.08.2022 | Examination fee paid | Examination procedure | 10.08.2022 | Examination requested [2023/01] | 10.08.2022 | Date on which the examining division has become responsible | 27.03.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 25.01.2023 | Renewal fee patent year 03 | 04.12.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2015004400 (UNIV RABELAIS FRANCOIS [FR]); | [Y]WO2017023780 (US HEALTH [US], et al); | [A]CN107715119 (UNIV SICHUAN); | [Y]CN107744592 (UNIV SICHUAN); | by applicant | US2018214568 |